Xeltis
Xeltis is an innovative medtech company dedicated to developing regenerative cardiovascular solutions that leverage endogenous tissue restoration (ETR) technology. With a focus on creating self-healing, durable vessels and valves, Xeltis aims to transform treatment options for vascular and heart diseases. The company conducts clinical trials for products like aXess, XABG, and Xplore, and has received significant investments and collaborations, including commitments from Grand Pharma and European funding. Xeltis's research demonstrates superior biocompatibility, reduced inflammation, and potential for long-term tissue regeneration, positioning it as a leader in regenerative cardiovascular medicine.
Industries
Nr. of Employees
small (1-50)
Patents
Method of using a cardiovascular graft to reduce thrombosis or platelet adhesion
US-11980535-B2
View Details
Method of using a cardiovascular graft to reduce thrombosis or platelet adhesion
US-11980535-B2
View DetailsProducts
aXess
An implantable vascular graft designed for hemodialysis access that promotes endogenous tissue restoration, currently in pivotal clinical trials.
XABG
A synthetic coronary artery bypass graft that transforms into a living vessel, demonstrating unprecedented preclinical outcomes and in clinical trials.
Xplore 2
A pulmonary heart valve that leverages Xeltis' ETR platform to create living, durable valves for pediatric and adult patients.
aXess-S
Straight configuration of the aXess Hemodialysis Conduit with a 24 cm length.
aXess-L
Loop configuration of the aXess Hemodialysis Conduit with a 32 cm length.
XABG coronary artery bypass conduit
A novel coronary artery bypass conduit evaluated in first-in-human clinical studies.
aXess
An implantable vascular graft designed for hemodialysis access that promotes endogenous tissue restoration, currently in pivotal clinical trials.
XABG
A synthetic coronary artery bypass graft that transforms into a living vessel, demonstrating unprecedented preclinical outcomes and in clinical trials.
Xplore 2
A pulmonary heart valve that leverages Xeltis' ETR platform to create living, durable valves for pediatric and adult patients.
aXess-S
Straight configuration of the aXess Hemodialysis Conduit with a 24 cm length.
aXess-L
Loop configuration of the aXess Hemodialysis Conduit with a 32 cm length.
XABG coronary artery bypass conduit
A novel coronary artery bypass conduit evaluated in first-in-human clinical studies.
News & Updates
Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council
Xeltis passes evaluation for a €10 million investment from the European Innovation Council, supporting clinical programs for its restorative devices.
Xeltis lands €15 million European financing from EIB
The European Investment Bank signs a €15 million financing agreement to support Xeltis' clinical development of its innovative cardiovascular devices.
Xeltis raises €32 million to drive clinical development of its advanced devices
A Series D2 funding round backed by international investors including DaVita Venture Group and EQT Life Sciences to accelerate clinical trials.
Xeltis’ aXess implanted in first patient in Poland
The first implantation of the aXess vascular graft in Poland as part of the pivotal trial for dialysis patients.
Preclinical outcomes for Xeltis’ CABG device may outperform saphenous veins
Preclinical data shows unprecedented one-year patency for XABG, potentially superior to saphenous veins, in large animal studies.
Xeltis’ bio-restorative technology published in Frontiers
Early outcomes from clinical trials demonstrating safety and performance of Xeltis' bio-restorative pulmonary valve.
Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council
Xeltis passes evaluation for a €10 million investment from the European Innovation Council, supporting clinical programs for its restorative devices.
Xeltis lands €15 million European financing from EIB
The European Investment Bank signs a €15 million financing agreement to support Xeltis' clinical development of its innovative cardiovascular devices.
Xeltis raises €32 million to drive clinical development of its advanced devices
A Series D2 funding round backed by international investors including DaVita Venture Group and EQT Life Sciences to accelerate clinical trials.
Xeltis’ aXess implanted in first patient in Poland
The first implantation of the aXess vascular graft in Poland as part of the pivotal trial for dialysis patients.
Preclinical outcomes for Xeltis’ CABG device may outperform saphenous veins
Preclinical data shows unprecedented one-year patency for XABG, potentially superior to saphenous veins, in large animal studies.
Xeltis’ bio-restorative technology published in Frontiers
Early outcomes from clinical trials demonstrating safety and performance of Xeltis' bio-restorative pulmonary valve.